Effectiveness of Deep Versus Moderate Neuromuscular Blockade

• Status: Completed
• Trial end date: 2018-11-02
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the influence of depth of neuromuscular blockade during laparoscopic gastrectomy on postoperative pain in surgical patients allocated randomly to either deep or moderate neuromuscular blockade group with standard-pressure pneumoperitoneum of 13 mmHg.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Treatments: Rocuronium

Criteria

Inclusion Criteria:

• Patients 20 to 65 years old

• American Society of Anesthesiologist Physical Status 1, 2 or 3

• Patients undergoing laparoscopic gastrectomy

• Patients who signed a written informed consent form

Exclusion Criteria:

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test

• Patients with known hypersensitivity to rocuronium or sugammadex

• Patient with VAS score (0=no pain; 100=the most severe pain) of at least 10 before surgery

• Patients with liver cirrhosis confirmed by abdominal CT

• Patients with neuromuscular disease that may interfere with neuromuscular data (ex. Duchenne muscular dystrophy, myasthenia gravis)

• Clinically significant impairment of cardiovascular function, defined by ejection fraction < 50%

• Clinically significant impairment of renal function, defined by estimated GFR < 60 ml/min or need for hemodialysis

• Clinically significant impairment of liver function, defined by alanine aminotransferase > 100 IU/L

• Indication for rapid sequence induction

• Use of opioids within the 7 days prior to surgery

• History of abdominal surgery

• History of chronic obstructive pulmonary disease

• Body mass index (BMI) ≥ 35 kg/m2

• Body weight < 50 kg

• Conversion to laparotomy

• Family history of malignant hyperthermia

• Patients who are considered by the investigator to be unsuitable to participate in the study for any other reason not mentioned in the inclusion and exclusion criteria